Tourmaline Bio (TRML, Financial) has shared positive results from its Phase 2 TRANQUILITY trial, which assesses both quarterly and monthly subcutaneous doses of pacibekitug for patients with chronic kidney disease and elevated high-sensitivity C-reactive protein (hs-CRP) levels. This biomarker is known to be linked with increased cardiovascular risk. The TRANQUILITY trial serves as an initial step in Tourmaline's development program for pacibekitug, aimed at atherosclerotic cardiovascular disease and other related conditions.
The company is actively progressing its clinical strategy for pacibekitug to address cardiovascular inflammation and is exploring Phase 3 trial possibilities for patients with atherosclerotic cardiovascular disease (ASCVD). Furthermore, Tourmaline plans to launch a Phase 2 proof-of-concept trial focusing on abdominal aortic aneurysm patients in the latter half of 2025.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for Tourmaline Bio Inc (TRML, Financial) is $55.20 with a high estimate of $70.00 and a low estimate of $35.00. The average target implies an upside of 231.93% from the current price of $16.63. More detailed estimate data can be found on the Tourmaline Bio Inc (TRML) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Tourmaline Bio Inc's (TRML, Financial) average brokerage recommendation is currently 1.6, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
